• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
    Get the next $ACTU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    8/26/2025$20.00Buy
    B. Riley Securities
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

    Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated regulatory inflection pointsAdditional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through

    9/22/25 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

    CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price, before underwriting discounts and commissions, for each share of com

    9/11/25 4:01:00 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

    CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common stock. Actuate has granted the underwriters a 30-day option to purchase up to 321,428 additional shares of its common stock sold in the offering at the public offering price per share, less underwriti

    9/10/25 8:31:02 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    SEC Filings

    View All

    Actuate Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/10/25 5:11:14 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Actuate Therapeutics Inc.

    424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/10/25 5:05:01 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Actuate Therapeutics Inc.

    424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/9/25 4:01:38 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Actuate Therapeutics with a new price target

    B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    8/26/25 8:17:26 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

    Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

    4/22/25 8:00:39 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Actuate Therapeutics Inc.

    SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

    8/19/24 8:59:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care